Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
News 02.11.2022 Schlieren (Zurich), Switzerland, November 2, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the completion of enrolment in the Level 1 clinical study, comparing MagnetOs Granules to the gold standard of autograft bone in patients undergoing posterolateral lumbar fusion. Data from...